ESPID Issues First Pediatric Invasive Group A Streptococcal Management Guidelines

ESPID provides the first dedicated pediatric iGAS framework, clarifying when adjunctive clindamycin, linezolid, IVIG, and contact chemoprophylaxis are warranted amid rising incidence and clindamycin resistance.

ESPID pediatric iGAS guidelineEuropean Society for Pediatric Infectious Diseaseinvasive group A streptococcuspenicillinsclindamycinlinezolidIVIGchemoprophylaxis Infectious Disease / Antimicrobials

Background Information

Penicillins lead the charge against pediatric iGAS infections.

Invasive Group A Streptococcal (iGAS) infections in children are rare but serious, with increasing incidence. Penicillins are first-line; clindamycin and linezolid are alternatives for severe cases. Intravenous immunoglobulin (IVIG) may be used in life-threatening situations. Recommendations are based on low-quality evidence, indicating a need for more robust pediatric studies. Penicillins remain the cornerstone for treating pediatric iGAS infections.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Chiappini E, Pellegrino R, Dalpiaz I, Renni M, Vergadi E, Ivaska L, Romani L, Avcu G, Milani G, Danino D

Citation: Chiappini E, Pellegrino R, Dalpiaz I, et al. Management of Invasive Group A Streptococcal Infections in Children: The European Society for Pediatric Infectious Disease Guidelines. The Pediatric infectious disease journal. 2026. doi:10.1097/INF.0000000000005336

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →